Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Newly-Diagnosed Anaplastic Astrocytoma

Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with rare brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company’s clinical stage products Antineoplaston A10 injections (Atengenal^®) and Antineoplaston AS2-1 injections (Astugenal^®). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.

The phase II, single-arm, two-stage, interventional trial was conducted in the United States and evaluated adults with newly-diagnosed anaplastic astrocytoma (AA). The study was closed for admission after enrollment of 19 adults out of a planned 40 patients, as the goal for complete response had been met in four study eligible patients. Progression-free survival (PFS) and overall survival (OS) at 1, 2, 3, 5 and 10 years are presented. A small number of patients experienced serious, but reversible Grade 3 and 4 toxicities, including hypernatremia, hypokalemia and somnolence. No chronic toxicities were noted.

The publication entitled, “A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Newly-Diagnosed Anaplastic Astrocytoma” was published in Cancer and Clinical Oncology 2015; 4(1):28-38.

About Burzynski Research Institute, Inc.

Burzynski Research Institute, Inc. (OTCBB: BZYR) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and development efforts are focused on basic research and phase 3 clinical trials, particularly in the treatment of brain tumors and other forms of cancer.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to an ability to use Antineoplastons A10 and AS2-1. Burzynski Research Institute, Inc. does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.